Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387948 | 1.00 | SMYD3 (0.40) | SMYD3CACNA1GCACNA1HCACNA1IMET | |
| SCHEMBL4543009 | 0.85 | CACNA1I (0.54) | SMYD3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL4392712 | 0.85 | CACNA1I (0.54) | SMYD3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL4390575 | 0.83 | SMYD3 (0.46) | SMYD3 | |
| SCHEMBL27573026 | 0.82 | SMYD3 (0.39) | SMYD3ADRA1DADRA1AADRA1B | |
| SCHEMBL4387325 | 0.75 | SMYD3 (0.33) | SMYD3 | |
| SCHEMBL27530303 | 0.75 | SMYD3 (0.33) | SMYD3 | |
| SCHEMBL27579299 | 0.74 | SMYD3 (0.44) | SMYD3 | |
| SCHEMBL4397105 | 0.73 | F10 (0.44) | ADRA1DADRA1AADRA1B | |
| SCHEMBL27591191 | 0.73 | KIT (0.41) | CACNA1GCACNA1HCACNA1IMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1051176-B1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMA INC (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | SMYD3 4406/4885CACNA1G 3668/4885CACNA1H 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.